International, Peer Reviewed, Open Access Journal

Cancer Clinics Journal
(ISSN: 2689-9566)

Submit Manuscript

Cancer Clinics Journal

Cancer Clinics Journal (ISSN: 2689-9566) is a peer reviewed open access journal aims to publish significant and up-to-date articles within the fields of experimental and clinical oncology including carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; epidemiology and strategies for prevention, diagnosis, treatment, and cure for cancer.

Journal Features

Open Access

All the articles will be published under Open Access model.

Peer Review

Our editorial team performs strict peer-review process.

Publication Ethics

The journal follows standard guidelines to maintain transparency.

Submit Manuscript

The journal accepts all original articles, reviews and more.

About the Journal

Cancer Clinics Journal (ISSN: 2689-9566) is a peer reviewed open access journal aims to publish significant and up-to-date articles within the fields of experimental and clinical oncology including carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; epidemiology and strategies for prevention, diagnosis, treatment, and cure for cancer.

Open Access - Cancer Clinics Journal

Editorial Board

Soldano Ferrone - Cancer Clinics Journal

Soldano Ferrone

Harvard Medical School
United States

Girijesh Kumar Patel - Cancer Clinics Journal

Girijesh Kumar Patel

University of South Alabama
United States

Yongqing Liu - Cancer Clinics Journal

Yongqing Liu

University of Louisville
United States

Alireza Heidari - Cancer Clinics Journal

Alireza Heidari

California South University
United States

Mohammad Aslam Khan - Cancer Clinics Journal

Mohammad Aslam Khan

University of South Alabama-Mitchell Cancer Institute
United States

Maria Angelica Cortez - Cancer Clinics Journal

Maria Angelica Cortez

The University of Texas MD Anderson Cancer Center
United States

Hexin Chen - Cancer Clinics Journal

Hexin Chen

University of South Carolina
United States

Shanta M. Messerli - Cancer Clinics Journal

Shanta M. Messerli

Sanford Research
United States

Susana Maria Campos - Cancer Clinics Journal

Susana Maria Campos

Dana-Farber Cancer Institute
United States

Randa A. El-Zein - Cancer Clinics Journal

Randa A. El-Zein

Houston Methodist Hospital Houston
United States

Peter C. Hu - Cancer Clinics Journal

Peter C. Hu

The University of Texas MD Anderson Cancer Center
United States

Sanjeev K. Srivastava - Cancer Clinics Journal

Sanjeev K. Srivastava

University of South Alabama
United States

Articles

Cancer Clin J. 2020;2(1):CCJ-02-1012 | Open Access

The Effect of Acupuncture on Obstructive Jaundice Secondary to Metastatic Gastric Cancer after Failure of Percutaneous Transhepatic Cholangiography and Drainage: A Case Report

Qi Min, Ting Chen and Yongjie Zhang

Obstructive jaundice is a rare complication of gastric cancer and portends poor prognosis. Percutaneous biliary drainage or implantation of biliary stents are commonly used treatment. In our case who was afflicted with biliary obstruction secondary to metastatic gastric cancer, Percutaneous Transhepatic Cholangiography and Drainage (PTCD) was performed, however, the efficacy was not optimistic, as shown by sustained elevation of serum ... Read more

CASE REPORT Updated Nov 02, 2020   PDF

Cancer Clin J. 2020;2(1):CCJ-02-1011 | Open Access

Bladder Cancer New Biomarkers in Liquid Biopsies

Gil Falcão, João Vasco Barreira, Anuraj Parmanande, Cabrita Carneiro and Luís Campos Pinheiro

Bladder cancer is one of the most common neoplasia in men in the developed countries. Diagnosis and surveillance are made by bladder examination through cystoscopy making this one of the most expensive on cost/patient. After tumor removal, clinical staging is important for prognosis and treatment decision as non-muscle invasive (Ta and T1) and invasive (T2+) are treated in a ... Read more

RESEARCH ARTICLE Updated Aug 25, 2020   PDF

Cancer Clin J. 2020;2(1):CCJ-02-1010 | Open Access

Can Systemic Photobiomodulation Help Coronavirus Anti- Viral Immunity?

Juliano Abreu Pacheco

In times of personal and scientific uncertainty, the world has become insecure and confused, causing a dark impact on humanity due to a small being, less than 0.2 μm, formed by a protective capsule and genetic material. Nice to meet you: Covid-19 disease, SARSCoV- 2 virus and family of corona viruses. This pandemic disease has a characteristic of high interpersonal contagion ... Read more

OPINION Updated May 11, 2020   PDF

Cancer Clin J. 2019;1(2):CCJ-01-1009 | Open Access

Bifidobacterium-Based Therapeutics: is Procalcitonin a Possible Systemic Measurement of Detection?

Kendra Lian, Emmanouil Alimpertis, Laura Stanbery and John Nemunaitis

In the current era of precision oncology therapeutics, impressive developments have been made to increase the efficacy of site-specific drug delivery systems to solid tumors, thereby avoiding the offtarget side effects traditionally seen in systemic delivery of cytotoxic chemotherapies. This approach also increases the concentration of drug directly at the site of the tumor. The incorporation of anticancer agents into ... Read more

EDITORIAL Updated Dec 30, 2019   PDF

Cancer Clin J. 2019;1(2):CCJ-01-1008 | Open Access

Sustained Target Lesion Shrinkage and Favorable Survival Outcome in Radiation and Radio-Chemotherapy Resistant High Grade Glioma Treated by Convection Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic

Fatih M Uckun, Sanjive Qazi, Larn Hwang and Vuong N Trieu

Here we report the single agent activity of the TGFβ2-specific synthetic RNA therapeutic OT101 in a select group of 12 patients with high-grade glioma who had experienced their recurrence >90 days after radiation (12 patients; 100%) or radiation + concomitant chemotherapy (8 patients; 67%). OT101 was administered intratumorally for up to 5 months by continuous infusion via. a Convection-Enhanced Delivery (CED) platform, CEDOT, designed to ... Read more

RESEARCH ARTICLE Updated Dec 26, 2019   PDF